494 related articles for article (PubMed ID: 11786932)
1. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
2. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
3. Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK; Nair S
Int J Mol Med; 2001 Aug; 8(2):193-8. PubMed ID: 11445874
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
6. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of c-myc proto-oncogene in primary human breast carcinomas.
Pavelic ZP; Steele P; Preisler HD
Anticancer Res; 1991; 11(4):1421-7. PubMed ID: 1660688
[TBL] [Abstract][Full Text] [Related]
9. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
10. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.
Pavelic ZP; Pavelic L; Lower EE; Gapany M; Gapany S; Barker EA; Preisler HD
Cancer Res; 1992 May; 52(9):2597-602. PubMed ID: 1348967
[TBL] [Abstract][Full Text] [Related]
11. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
12. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
13. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
Anticancer Res; 1995; 15(3):959-64. PubMed ID: 7645986
[TBL] [Abstract][Full Text] [Related]
15. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.
Vos CB; Ter Haar NT; Peterse JL; Cornelisse CJ; van de Vijver MJ
J Pathol; 1999 Feb; 187(3):279-84. PubMed ID: 10398079
[TBL] [Abstract][Full Text] [Related]
20. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
